|
1) Sherr CJ. Mammalian G1 cyclins and cell cycle progression. Proc Assoc Am Physicians. 1995; 107: 181-6
|
|
|
|
2) Nurse P. Ordering S phase and M phase in the cell cycle. Cell. 1994; 79: 547-50
|
|
|
|
|
3) Shiozawa T, Miyamoto T, Kashima H, et al. Estrogen-induced proliferation of normal endometrial glandular cells is initiated by transcriptional activation of cyclin D1 via binding of c-Jun to an AP-1 sequence. Oncogene. 2004; 23: 8603-10
|
|
|
|
|
|
4) Kolch W. Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000; 351: 289-305
|
|
|
|
|
|
5) Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001; 93: 53-62
|
|
|
|
|
|
6) Pierro E, Minici F, Alesiani O, et al. Stromal-epithelial interactions modulate estrogen responsiveness in normal human endometrium. Biol Reprod. 2001; 64: 831-8
|
|
|
|
|
|
7) Suga S, Kato K, Ohgami T, et al. An inhibitory effect on cell proliferation by blockage of the MAPK/estrogen receptor/MDM2 signal pathway in gynecologic cancer. Gynecol Oncol. 2007; 105: 341-50
|
|
|
|
|
|
8) Guo RX, Wei LH, Tu Z, et al. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ER-independent mechanisms in endometrial cancer cells. J Steroid Biochem Mol Biol. 2006; 99: 9-18
|
|
|
|
|
|
9) Chan TA, Hwang PM, Hermeking H, et al. Cooperative effects of genes controlling the G(2)/M checkpoint. Genes Dev. 2000; 14: 1584-8
|
|
|
|
|
|
10) Urano T, Saito T, Tsukui T, et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature. 2002; 417: 871-5
|
|
|
|
|
|
11) Nakayama H, Sano T, Motegi A, et al. Increasing 14-3-3 sigma expression with declining estrogen receptor alpha and estrogen-responsive finger protein expression defines malignant progression of endometrial carcinoma. Pathol Int. 2005; 55: 707-15
|
|
|
|
|
12) Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology. 2007; 39: 72-87
|
|
|
|
|
|
13) Yager JD. Endogenous estrogens as carcinogens through metabolic activation. J Natl Cancer Inst Monogr. 2000; 27: 67-73
|
|
|
|
|
|
14) Sasaki M, Kaneuchi M, Sakuragi N, et al. Multiple promoters of catechol-O-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer. Cancer Res. 2003; 63: 3101-6
|
|
|
|
|
|
15) Esinler I, Aktas D, Alikasifoglu M, et al. CYP1A1 gene polymorphism and risk of endometrial hyperplasia and endometrial carcinoma. Int J Gynecol Cancer. 2006; 16: 1407-11
|
|
|
|
|
|
16) Schwarz D, Kisselev P, Schunck WH, et al. Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000; 10: 519-30
|
|
|
|
|
|
17) Sugawara T, Nomura E, Sagawa T, et al. CYP1A1 polymorphism and risk of gynecological malignancy in Japan. Int J Gynecol Cancer. 2003; 13: 785-90
|
|
|
|
|
|
18) Paynter RA, Hankinson SE, Colditz GA, et al. CYP19 (aromatase) haplotypes and endometrial cancer risk. Int J Cancer. 2005; 116: 267-74
|
|
|
|
|
|
19) Berstein LM, Imyanitov EN, Suspitsin EN, et al. CYP19 gene polymorphism in endometrial cancer patients. J Cancer Res Clin Oncol. 2001; 127: 135-8
|
|
|
|
|
|
20) Rebbeck TR, Troxel AB, Wang Y, et al. Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J Natl Cancer Inst. 2006; 98: 1311-20
|
|
|
|
|
|
21) Phillips DH. Understanding the genotoxicity of tamoxifen？ Carcinogenesis. 2001; 22: 839-49
|
|
|
|
|
|
22) White IN. Tamoxifen: is it safe？ Comparison of activation and detoxication mechanisms in rodents and in humans. Curr Drug Metab. 2003; 4: 223-39
|
|
|
|
|
|
23) Besaratinia A, Pfeifer GP. Investigating DNA adduct-targeted mutagenicity of tamoxifen: preferential formation of tamoxifen-DNA adducts in the human p53 gene in SV40 immortalized hepatocytes but not endometrial carcinoma cells. Biochemistry. 2005; 44: 8418-27
|
|
|
|
|
|
24) Caldes T, Perez-Segura P, Tosar A, et al. Microsatellite instability correlates with negative expression of estrogen and progesterone receptors in sporadic breast cancer. Teratog Carcinog Mutagen. 2000; 20: 283-91
|
|
|
|
|
|
25) Slattery ML, Potter JD, Curtin K et al. Estrogens reduce and withdrawal of estrogens increase risk of microsatellite instability-positive colon cancer. Cancer Res. 2001; 61: 126-30
|
|
|
|
|
|
26) Miyamoto T, Shiozawa T, Kashima H, et al. Estrogen up-regulates mismatch repair activity in normal and malignant endometrial glandular cells. Endocrinology. 2006; 147: 4863-70
|
|
|
|
|